Efeitos do polimorfismo T-786C do gene da óxido nítrico sintase endotelial (eNOS) e/ou da atorvastatina sobre parâmetros do metabolismo lipídico em adultos assintmáticos / Effects of the polymorphism T-786C of endothelial nitric oxide synthase (eNOS) gene and/or atorvastatin on parameters of lipid metabolism in asymptomatic adults

AUTOR(ES)
FONTE

IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia

DATA DE PUBLICAÇÃO

11/08/2010

RESUMO

Nitric oxide (NO) is produced in the vascular endothelium by endothelial nitric oxide synthase (eNOS), an enzyme negatively regulated by the presence of the T-786C polymorphism, leading to endothelial dysfunction. High-density lipoproteins (HDL) have well-established anti-atherogenic functions, for example mechanisms that enhance eNOS activity. Statins are drugs that have pleiotropic effects, such as the improvement in endothelial function and beneficial composition of HDL. Taking into account both the activity of eNOS on endothelial function, and the validity of the pleiotropic effects of statins, we evaluated the biochemical parameters and the composition of subfractions of HDL (HDL2 and HDL3) after use of placebo and atorvastatin at a dose of 10mg/day for 14 days, in a population sample of 30 individuals divided into two genotype groups of the T-786C polymorphism of the eNOS gene: CC (carriers) or TT (non-carriers). Two hundred individuals were genotyped, and the selected groups paired by age and BMI. The serum parameters analyzed were determined using biochemical enzymatic, radiometric, nephelometric and microultracentrifugation methods. We measured lipids, lipoproteins, the composition of sub-fractions of HDL (HDL2 and HDL3), apolipoproteins, activity of cholesteryl ester transfer protein, NO metabolites and hsCRP. After statin, as expected, drastic effects were observed both in lipids, lipoproteins, apolipoproteins, independently of the polymorphism. In HDL sub-fractions the ratio lipid/protein was smaller in both HDL2 and HDL3. CETP activity and free fatty acids were reduced in a polymorphism-dependent manner, and the reduction of nitrite was polymorphism-independent. hsCRP did not change. Atorvastatin may have acted on the reverse cholesterol transport by reducing the activity of hepatic lipase, increased PLTP activity and reducing CETP. There was a genotype/drug interaction effect on CETP and Lp(a). These results suggest that statin treatment may be relevant for primary prevention of atherosclerosis in patients with the polymorphism, irrespective of serum lipid changes. These individuals would benefit from the use of statins because of reduction of CETP activity and free fatty acids.

ASSUNTO(S)

lipoproteinas lipoproteinas hdl lipoproteínas hdl2 lipoproteínas hdl3 oxido nitrico sintase tipo iii lipoproteins lipoproteins hdl lipoproteins hdl2 lipoproteins hdl3 nitric oxide synthase type iii

ACESSO AO ARTIGO

Documentos Relacionados